Eight years without a new option. Now there is one.
Depois de oito anos sem novas opções terapêuticas, o Brasil deu um passo significativo no enfrentamento de um dos cânceres mais letais entre mulheres. A Anvisa aprovou o mirvetuximabe soravtansina — Elahere — para pacientes com câncer de ovário resistente à quimioterapia, marcando o fim de uma longa espera para cerca de 7.300 brasileiras diagnosticadas anualmente com a doença. O medicamento age com precisão sobre um receptor proteico específico, poupando tecidos saudáveis e oferecendo, pela primeira vez em fase 3, evidência de benefício real na sobrevida global — um lembrete de que o progresso científico, quando chega, carrega consigo o peso de vidas que esperaram por ele.
- O câncer de ovário mata mais mulheres do que qualquer outro câncer ginecológico no mundo, e no Brasil a maioria dos casos é diagnosticada já em estágio avançado — tornando cada nova opção de tratamento uma questão de urgência real.
- Por oito anos, pacientes com doença resistente à platina não tiveram nenhuma alternativa terapêutica aprovada no país, um vazio que o Elahere agora vem preencher.
- Os dados clínicos são concretos: redução de 35% no risco de progressão da doença e sobrevida mediana ampliada de 12,7 para 16,5 meses em comparação à quimioterapia convencional.
- O acesso ao tratamento exige um teste de imuno-histoquímica para identificar pacientes com alta expressão do receptor folato alfa — critério que direciona o medicamento a quem tem maior chance de resposta.
- A aprovação pela Anvisa é apenas o primeiro degrau: a inclusão no plano de saúde suplementar (ANS) e no SUS ainda depende de decisões futuras, mantendo a questão do acesso em aberto.
A Anvisa aprovou o mirvetuximabe soravtansina, comercializado como Elahere, para o tratamento do câncer de ovário em pacientes cujos tumores deixaram de responder à quimioterapia. O medicamento atua sobre o receptor de folato alfa, uma proteína presente em aproximadamente um terço dos tumores ovarianos, destruindo células cancerígenas com menor impacto sobre os tecidos saudáveis.
A aprovação encerra um intervalo de oito anos sem novas opções para casos resistentes à platina no Brasil — um período longo demais para uma doença que diagnostica cerca de 7.300 mulheres por ano no país, quase sempre em estágios avançados. O câncer de ovário lidera a mortalidade entre os cânceres ginecológicos globalmente, e sua tendência de retornar após o tratamento inicial torna cada mês adicional de sobrevida clinicamente relevante.
Os resultados do ensaio clínico com mais de 450 pacientes sustentam o otimismo: além da redução de 35% no risco de progressão, a taxa de redução tumoral foi de 42% no grupo tratado com Elahere, contra 16% no grupo de quimioterapia. Para ter acesso ao medicamento, as pacientes precisarão realizar um teste laboratorial — já disponível no Brasil — que identifica a expressão elevada do receptor-alvo.
A aprovação regulatória, porém, não garante acesso imediato. A cobertura pelo sistema de saúde suplementar e a incorporação ao SUS ainda dependem de processos separados. O Elahere existe legalmente no país, mas seu alcance real ainda será definido pelas decisões que virão.
Brazil's health regulator has cleared a new weapon against one of the country's deadliest cancers. The Anvisa approved mirvetuximabe soravtansina—marketed as Elahere—for ovarian cancer patients whose tumors no longer respond to chemotherapy. The drug targets a specific protein called folate alpha receptor, which appears on roughly one-third of ovarian cancer cells, and works by destroying tumors while largely sparing healthy tissue.
The approval matters because it ends an eight-year drought. No new treatment option for platinum-resistant ovarian cancer has reached Brazilian patients since the mid-2010s. The disease itself is relentless: it kills more women than any other gynecological cancer globally, and in Brazil alone, doctors expect to diagnose about 7,300 new cases this year. Most arrive at the clinic already advanced, and most return after initial treatment ends.
Elahere's clinical evidence is substantial. A trial involving more than 450 patients showed the drug cut the risk of disease progression by 35 percent. Median survival stretched to 16.5 months for those who received it, compared to 12.7 months for those treated with chemotherapy alone. Tumor shrinkage occurred in 42 percent of patients on Elahere versus 16 percent in the comparison group. These are the kinds of numbers that matter to someone facing a recurrence—months of additional life, a chance at more time.
The path forward has a practical gate. Doctors will need to run an immunohistochemistry test, already available in Brazilian labs, to identify which patients have tumors expressing high levels of the folate alpha receptor. Only those patients will benefit from the drug. This precision matters: it means the treatment goes to people most likely to respond, not scattered across a broad population.
What remains uncertain is access. The Anvisa approval is one step. Whether Elahere will be covered by Brazil's supplementary health insurance system (ANS) or folded into the public health system (SUS) has not yet been decided. For now, the drug exists in the country legally, but its reach depends on decisions still to come. Still, for patients and their doctors, the approval itself signals that the long wait for new options has ended.
Citações Notáveis
This is the first therapy to demonstrate overall survival benefit in phase 3 trials for patients with folate alpha receptor-positive tumors— AbbVie (pharmaceutical company conducting the trial)
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this is the first new treatment in eight years?
Because ovarian cancer doesn't stop. Women finish chemotherapy, go into remission, and then it comes back. When it does, their old drugs often don't work anymore. For eight years, doctors had almost nothing new to offer them. Now they do.
How does the drug actually work differently from chemotherapy?
Chemotherapy is a blunt instrument—it poisons fast-dividing cells, but it damages healthy ones too. Elahere is more like a guided missile. It looks for a specific protein on cancer cells and attaches to it, then delivers its payload directly. Most healthy cells don't have that protein, so they're spared.
The trial showed 16.5 months versus 12.7 months. That's less than four months more. Is that significant?
For someone facing recurrence, yes. Four months is real time. It's holidays, conversations, plans. And the tumor shrinkage rate—42 percent versus 16 percent—suggests the drug is actually working, not just extending a decline.
What's the catch with the immunohistochemistry test?
There isn't really one. The test already exists in Brazilian labs. It just means not every ovarian cancer patient will be eligible. Only those whose tumors express the folate alpha receptor will benefit. That's about a third of patients, but it's the right third.
So why isn't it automatically in the public health system?
Approval and coverage are different things. Anvisa says it's safe and effective. But SUS and the insurance system have to decide if they can afford it, how many patients need it, what it costs. That's still being worked out.
What happens to patients waiting for that decision?
They wait. Some may have private insurance that covers it sooner. Others may not have access at all until the system decides. That's the gap between approval and reality.